Gluconeogenesis

Last updated

Gluconeogenesis (GNG) is a metabolic pathway that results in the biosynthesis of glucose from certain non-carbohydrate carbon substrates. It is a ubiquitous process, present in plants, animals, fungi, bacteria, and other microorganisms. [1] In vertebrates, gluconeogenesis occurs mainly in the liver and, to a lesser extent, in the cortex of the kidneys. It is one of two primary mechanisms – the other being degradation of glycogen (glycogenolysis) – used by humans and many other animals to maintain blood sugar levels, avoiding low levels (hypoglycemia). [2] In ruminants, because dietary carbohydrates tend to be metabolized by rumen organisms, gluconeogenesis occurs regardless of fasting, low-carbohydrate diets, exercise, etc. [3] In many other animals, the process occurs during periods of fasting, starvation, low-carbohydrate diets, or intense exercise.

Contents

In humans, substrates for gluconeogenesis may come from any non-carbohydrate sources that can be converted to pyruvate or intermediates of glycolysis (see figure). For the breakdown of proteins, these substrates include glucogenic amino acids (although not ketogenic amino acids); from breakdown of lipids (such as triglycerides), they include glycerol, odd-chain fatty acids (although not even-chain fatty acids, see below); and from other parts of metabolism that includes lactate from the Cori cycle. Under conditions of prolonged fasting, acetone derived from ketone bodies can also serve as a substrate, providing a pathway from fatty acids to glucose. [4] Although most gluconeogenesis occurs in the liver, the relative contribution of gluconeogenesis by the kidney is increased in diabetes and prolonged fasting. [5]

The gluconeogenesis pathway is highly endergonic until it is coupled to the hydrolysis of ATP or GTP, effectively making the process exergonic. For example, the pathway leading from pyruvate to glucose-6-phosphate requires 4 molecules of ATP and 2 molecules of GTP to proceed spontaneously. These ATPs are supplied from fatty acid catabolism via beta oxidation. [6]

Precursors

Catabolism of proteinogenic amino acids. Amino acids are classified according to the abilities of their products to enter gluconeogenesis: Glucogenic amino acids have this ability Ketogenic amino acids do not. These products may still be used for ketogenesis or lipid synthesis. Some amino acids are catabolized into both glucogenic and ketogenic products. Amino acid catabolism revised.png
Catabolism of proteinogenic amino acids. Amino acids are classified according to the abilities of their products to enter gluconeogenesis:

In humans the main gluconeogenic precursors are lactate, glycerol (which is a part of the triglyceride molecule), alanine and glutamine. Altogether, they account for over 90% of the overall gluconeogenesis. [8] Other glucogenic amino acids and all citric acid cycle intermediates (through conversion to oxaloacetate) can also function as substrates for gluconeogenesis. [9] Generally, human consumption of gluconeogenic substrates in food does not result in increased gluconeogenesis. [10]

In ruminants, propionate is the principal gluconeogenic substrate. [3] [11] In nonruminants, including human beings, propionate arises from the β-oxidation of odd-chain and branched-chain fatty acids, and is a (relatively minor) substrate for gluconeogenesis. [12] [13]

Lactate is transported back to the liver where it is converted into pyruvate by the Cori cycle using the enzyme lactate dehydrogenase. Pyruvate, the first designated substrate of the gluconeogenic pathway, can then be used to generate glucose. [9] Transamination or deamination of amino acids facilitates entering of their carbon skeleton into the cycle directly (as pyruvate or oxaloacetate), or indirectly via the citric acid cycle. The contribution of Cori cycle lactate to overall glucose production increases with fasting duration. [14] Specifically, after 12, 20, and 40 hours of fasting by human volunteers, the contribution of Cori cycle lactate to gluconeogenesis was 41%, 71%, and 92%, respectively. [14]

Whether even-chain fatty acids can be converted into glucose in animals has been a longstanding question in biochemistry. [15] Odd-chain fatty acids can be oxidized to yield acetyl-CoA and propionyl-CoA, the latter serving as a precursor to succinyl-CoA, which can be converted to oxaloacetate and enter into gluconeogenesis. In contrast, even-chain fatty acids are oxidized to yield only acetyl-CoA, whose entry into gluconeogenesis requires the presence of a glyoxylate cycle (also known as glyoxylate shunt) to produce four-carbon dicarboxylic acid precursors. [9] The glyoxylate shunt comprises two enzymes, malate synthase and isocitrate lyase, and is present in fungi, plants, and bacteria. Despite some reports of glyoxylate shunt enzymatic activities detected in animal tissues, genes encoding both enzymatic functions have only been found in nematodes, in which they exist as a single bi-functional enzyme. [16] [17] Genes coding for malate synthase alone (but not isocitrate lyase) have been identified in other animals including arthropods, echinoderms, and even some vertebrates. Mammals found to possess the malate synthase gene include monotremes (platypus) and marsupials (opossum), but not placental mammals. [17]

The existence of the glyoxylate cycle in humans has not been established, and it is widely held that fatty acids cannot be converted to glucose in humans directly. Carbon-14 has been shown to end up in glucose when it is supplied in fatty acids, [18] but this can be expected from the incorporation of labelled atoms derived from acetyl-CoA into citric acid cycle intermediates which are interchangeable with those derived from other physiological sources, such as glucogenic amino acids. [15] In the absence of other glucogenic sources, the 2-carbon acetyl-CoA derived from the oxidation of fatty acids cannot produce a net yield of glucose via the citric acid cycle, since an equivalent two carbon atoms are released as carbon dioxide during the cycle. During ketosis, however, acetyl-CoA from fatty acids yields ketone bodies, including acetone, and up to ~60% of acetone may be oxidized in the liver to the pyruvate precursors acetol and methylglyoxal. [19] [4] Thus ketone bodies derived from fatty acids could account for up to 11% of gluconeogenesis during starvation. Catabolism of fatty acids also produces energy in the form of ATP that is necessary for the gluconeogenesis pathway.

Location

In mammals, gluconeogenesis has been believed to be restricted to the liver, [20] the kidney, [20] the intestine, [21] and muscle, [22] but recent evidence indicates gluconeogenesis occurring in astrocytes of the brain. [23] These organs use somewhat different gluconeogenic precursors. The liver preferentially uses lactate, glycerol, and glucogenic amino acids (especially alanine) while the kidney preferentially uses lactate, glutamine and glycerol. [24] [8] Lactate from the Cori cycle is quantitatively the largest source of substrate for gluconeogenesis, especially for the kidney. [8] The liver uses both glycogenolysis and gluconeogenesis to produce glucose, whereas the kidney only uses gluconeogenesis. [8] After a meal, the liver shifts to glycogen synthesis, whereas the kidney increases gluconeogenesis. [10] The intestine uses mostly glutamine and glycerol. [21]

Propionate is the principal substrate for gluconeogenesis in the ruminant liver, and the ruminant liver may make increased use of gluconeogenic amino acids (e.g., alanine) when glucose demand is increased. [25] The capacity of liver cells to use lactate for gluconeogenesis declines from the preruminant stage to the ruminant stage in calves and lambs. [26] In sheep kidney tissue, very high rates of gluconeogenesis from propionate have been observed. [26]

In all species, the formation of oxaloacetate from pyruvate and TCA cycle intermediates is restricted to the mitochondrion, and the enzymes that convert Phosphoenolpyruvic acid (PEP) to glucose-6-phosphate are found in the cytosol. [27] The location of the enzyme that links these two parts of gluconeogenesis by converting oxaloacetate to PEP – PEP carboxykinase (PEPCK) – is variable by species: it can be found entirely within the mitochondria, entirely within the cytosol, or dispersed evenly between the two, as it is in humans. [27] Transport of PEP across the mitochondrial membrane is accomplished by dedicated transport proteins; however no such proteins exist for oxaloacetate. [27] Therefore, in species that lack intra-mitochondrial PEPCK, oxaloacetate must be converted into malate or aspartate, exported from the mitochondrion, and converted back into oxaloacetate in order to allow gluconeogenesis to continue. [27]

Gluconeogenesis pathway with key molecules and enzymes. Many steps are the opposite of those found in the glycolysis. Gluconeogenesis pathway.png
Gluconeogenesis pathway with key molecules and enzymes. Many steps are the opposite of those found in the glycolysis.

Pathway

Gluconeogenesis is a pathway consisting of a series of eleven enzyme-catalyzed reactions. The pathway will begin in either the liver or kidney, in the mitochondria or cytoplasm of those cells, this being dependent on the substrate being used. Many of the reactions are the reverse of steps found in glycolysis.[ citation needed ]

Regulation

While most steps in gluconeogenesis are the reverse of those found in glycolysis, three regulated and strongly endergonic reactions are replaced with more kinetically favorable reactions. Hexokinase/glucokinase, phosphofructokinase, and pyruvate kinase enzymes of glycolysis are replaced with glucose-6-phosphatase, fructose-1,6-bisphosphatase, and PEP carboxykinase/pyruvate carboxylase. These enzymes are typically regulated by similar molecules, but with opposite results. For example, acetyl CoA and citrate activate gluconeogenesis enzymes (pyruvate carboxylase and fructose-1,6-bisphosphatase, respectively), while at the same time inhibiting the glycolytic enzyme pyruvate kinase. This system of reciprocal control allow glycolysis and gluconeogenesis to inhibit each other and prevents a futile cycle of synthesizing glucose to only break it down. Pyruvate kinase can be also bypassed by 86 pathways [28] not related to gluconeogenesis, for the purpose of forming pyruvate and subsequently lactate; some of these pathways use carbon atoms originated from glucose.

The majority of the enzymes responsible for gluconeogenesis are found in the cytosol; the exceptions are mitochondrial pyruvate carboxylase and, in animals, phosphoenolpyruvate carboxykinase. The latter exists as an isozyme located in both the mitochondrion and the cytosol. [29] The rate of gluconeogenesis is ultimately controlled by the action of a key enzyme, fructose-1,6-bisphosphatase, which is also regulated through signal transduction by cAMP and its phosphorylation.

Global control of gluconeogenesis is mediated by glucagon (released when blood glucose is low); it triggers phosphorylation of enzymes and regulatory proteins by Protein Kinase A (a cyclic AMP regulated kinase) resulting in inhibition of glycolysis and stimulation of gluconeogenesis. Insulin counteracts glucagon by inhibiting gluconeogenesis. Type 2 diabetes is marked by excess glucagon and insulin resistance from the body. [30] Insulin can no longer inhibit the gene expression of enzymes such as PEPCK which leads to increased levels of hyperglycemia in the body. [31] The anti-diabetic drug metformin reduces blood glucose primarily through inhibition of gluconeogenesis, overcoming the failure of insulin to inhibit gluconeogenesis due to insulin resistance. [32]

Studies have shown that the absence of hepatic glucose production has no major effect on the control of fasting plasma glucose concentration. Compensatory induction of gluconeogenesis occurs in the kidneys and intestine, driven by glucagon, glucocorticoids, and acidosis. [33]

Insulin resistance

In the liver, the FOX protein FOXO6 normally promotes gluconeogenesis in the fasted state, but insulin blocks FOXO6 upon feeding. [34] In a condition of insulin resistance, insulin fails to block FOXO6 resulting in continued gluconeogenesis even upon feeding, resulting in high blood glucose (hyperglycemia). [34]

Insulin resistance is a common feature of metabolic syndrome and type 2 diabetes. For this reason, gluconeogenesis is a target of therapy for type 2 diabetes, such as the antidiabetic drug metformin, which inhibits gluconeogenic glucose formation, and stimulates glucose uptake by cells. [35]

Origins

Gluconeogenesis is considered one of the most ancient anabolic pathways and is likely to have been exhibited in the last universal common ancestor. [36] Rafael F. Say and Georg Fuchs stated in 2010 that "all archaeal groups as well as the deeply branching bacterial lineages contain a bifunctional fructose 1,6-bisphosphate (FBP) aldolase/phosphatase with both FBP aldolase and FBP phosphatase activity. This enzyme is missing in most other Bacteria and in Eukaryota, and is heat-stabile even in mesophilic marine Crenarchaeota". It is proposed that fructose 1,6-bisphosphate aldolase/phosphatase was an ancestral gluconeogenic enzyme and had preceded glycolysis. [37] But the chemical mechanisms between gluconeogenesis and glycolysis, whether it is anabolic or catabolic, are similar, suggesting they both originated at the same time. Fructose 1,6-bisphosphate is shown to be nonenzymatically synthesized continuously within a freezing solution. The synthesis is accelerated in the presence of amino acids such as glycine and lysine implying that the first anabolic enzymes were amino acids. The prebiotic reactions in gluconeogenesis can also proceed nonenzymatically at dehydration-desiccation cycles. Such chemistry could have occurred in hydrothermal environments, including temperature gradients and cycling of freezing and thawing. Mineral surfaces might have played a role in the phosphorylation of metabolic intermediates from gluconeogenesis and have to been shown to produce tetrose, hexose phosphates, and pentose from formaldehyde, glyceraldehyde, and glycolaldehyde. [38] [39] [40]

See also

Related Research Articles

<span class="mw-page-title-main">Citric acid cycle</span> Interconnected biochemical reactions releasing energy

The citric acid cycle—also known as the Krebs cycle, Szent–Györgyi–Krebs cycle, or TCA cycle —is a series of biochemical reactions to release the energy stored in nutrients through the oxidation of acetyl-CoA derived from carbohydrates, fats, proteins, and alcohol. The chemical energy released is available in the form of ATP. The Krebs cycle is used by organisms that respire to generate energy, either by anaerobic respiration or aerobic respiration. In addition, the cycle provides precursors of certain amino acids, as well as the reducing agent NADH, that are used in numerous other reactions. Its central importance to many biochemical pathways suggests that it was one of the earliest components of metabolism. Even though it is branded as a "cycle", it is not necessary for metabolites to follow only one specific route; at least three alternative segments of the citric acid cycle have been recognized.

<span class="mw-page-title-main">Glycolysis</span> Series of interconnected biochemical reactions

Glycolysis is the metabolic pathway that converts glucose into pyruvate and, in most organisms, occurs in the liquid part of cells. The free energy released in this process is used to form the high-energy molecules adenosine triphosphate (ATP) and reduced nicotinamide adenine dinucleotide (NADH). Glycolysis is a sequence of ten reactions catalyzed by enzymes.

Pyruvic acid (CH3COCOOH) is the simplest of the alpha-keto acids, with a carboxylic acid and a ketone functional group. Pyruvate, the conjugate base, CH3COCOO−, is an intermediate in several metabolic pathways throughout the cell.

<span class="mw-page-title-main">Acetyl-CoA</span> Chemical compound

Acetyl-CoA is a molecule that participates in many biochemical reactions in protein, carbohydrate and lipid metabolism. Its main function is to deliver the acetyl group to the citric acid cycle to be oxidized for energy production.

<span class="mw-page-title-main">Anabolism</span> Metabolic pathways to build molecules

Anabolism is the set of metabolic pathways that construct macromolecules like DNA or RNA from smaller units. These reactions require energy, known also as an endergonic process. Anabolism is the building-up aspect of metabolism, whereas catabolism is the breaking-down aspect. Anabolism is usually synonymous with biosynthesis.

<span class="mw-page-title-main">Glucagon</span> Peptide hormone

Glucagon is a peptide hormone, produced by alpha cells of the pancreas. It raises the concentration of glucose and fatty acids in the bloodstream and is considered to be the main catabolic hormone of the body. It is also used as a medication to treat a number of health conditions. Its effect is opposite to that of insulin, which lowers extracellular glucose. It is produced from proglucagon, encoded by the GCG gene.

<span class="mw-page-title-main">Fructose 1,6-bisphosphatase</span> Class of enzymes

The enzyme fructose bisphosphatase (EC 3.1.3.11; systematic name D-fructose-1,6-bisphosphate 1-phosphohydrolase) catalyses the conversion of fructose-1,6-bisphosphate to fructose 6-phosphate in gluconeogenesis and the Calvin cycle, which are both anabolic pathways:

Carbohydrate metabolism is the whole of the biochemical processes responsible for the metabolic formation, breakdown, and interconversion of carbohydrates in living organisms.

<span class="mw-page-title-main">Pyruvate kinase</span> Class of enzymes

Pyruvate kinase is the enzyme involved in the last step of glycolysis. It catalyzes the transfer of a phosphate group from phosphoenolpyruvate (PEP) to adenosine diphosphate (ADP), yielding one molecule of pyruvate and one molecule of ATP. Pyruvate kinase was inappropriately named before it was recognized that it did not directly catalyze phosphorylation of pyruvate, which does not occur under physiological conditions. Pyruvate kinase is present in four distinct, tissue-specific isozymes in animals, each consisting of particular kinetic properties necessary to accommodate the variations in metabolic requirements of diverse tissues.

<span class="mw-page-title-main">Oxaloacetic acid</span> Organic compound

Oxaloacetic acid (also known as oxalacetic acid or OAA) is a crystalline organic compound with the chemical formula HO2CC(O)CH2CO2H. Oxaloacetic acid, in the form of its conjugate base oxaloacetate, is a metabolic intermediate in many processes that occur in animals. It takes part in gluconeogenesis, the urea cycle, the glyoxylate cycle, amino acid synthesis, fatty acid synthesis and the citric acid cycle.

Fatty acid metabolism consists of various metabolic processes involving or closely related to fatty acids, a family of molecules classified within the lipid macronutrient category. These processes can mainly be divided into (1) catabolic processes that generate energy and (2) anabolic processes where they serve as building blocks for other compounds.

<span class="mw-page-title-main">Cori cycle</span> Series of interconnected biochemical reactions

The Cori cycle, named after its discoverers, Carl Ferdinand Cori and Gerty Cori, is a metabolic pathway in which lactate, produced by anaerobic glycolysis in muscles, is transported to the liver and converted to glucose, which then returns to the muscles and is cyclically metabolized back to lactate.

<span class="mw-page-title-main">Pyruvate carboxylase</span> Enzyme

Pyruvate carboxylase (PC) encoded by the gene PC is an enzyme of the ligase class that catalyzes the physiologically irreversible carboxylation of pyruvate to form oxaloacetate (OAA).

<span class="mw-page-title-main">Fructose-bisphosphate aldolase</span> Protein family

Fructose-bisphosphate aldolase, often just aldolase, is an enzyme catalyzing a reversible reaction that splits the aldol, fructose 1,6-bisphosphate, into the triose phosphates dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (G3P). Aldolase can also produce DHAP from other (3S,4R)-ketose 1-phosphates such as fructose 1-phosphate and sedoheptulose 1,7-bisphosphate. Gluconeogenesis and the Calvin cycle, which are anabolic pathways, use the reverse reaction. Glycolysis, a catabolic pathway, uses the forward reaction. Aldolase is divided into two classes by mechanism.

<span class="mw-page-title-main">Inborn errors of carbohydrate metabolism</span> Medical condition

Inborn errors of carbohydrate metabolism are inborn error of metabolism that affect the catabolism and anabolism of carbohydrates.

Fructolysis refers to the metabolism of fructose from dietary sources. Though the metabolism of glucose through glycolysis uses many of the same enzymes and intermediate structures as those in fructolysis, the two sugars have very different metabolic fates in human metabolism. Under one percent of ingested fructose is directly converted to plasma triglyceride. 29% - 54% of fructose is converted in liver to glucose, and about a quarter of fructose is converted to lactate. 15% - 18% is converted to glycogen. Glucose and lactate are then used normally as energy to fuel cells all over the body.

Metabolic intermediates are compounds produced during the conversion of substrates into final products in biochemical reactions within cells.

Glyceroneogenesis is a metabolic pathway which synthesizes glycerol 3-phosphate from precursors other than glucose. Usually, glycerol 3-phosphate is generated from glucose by glycolysis, in the liquid of the cell's cytoplasm. Glyceroneogenesis is used when the concentrations of glucose in the cytosol are low, and typically uses pyruvate as the precursor, but can also use alanine, glutamine, or any substances from the TCA cycle. The main regulator enzyme for this pathway is an enzyme called phosphoenolpyruvate carboxykinase (PEPC-K), which catalyzes the decarboxylation of oxaloacetate to phosphoenolpyruvate. Glyceroneogenesis is observed mainly in adipose tissue, and in the liver. A significant biochemical pathway regulates cytosolic lipid levels. Intense suppression of glyceroneogenesis may lead to metabolic disorders such as type 2 diabetes.

Pseudohypoxia refers to a condition that mimics hypoxia, by having sufficient oxygen yet impaired mitochondrial respiration due to a deficiency of necessary co-enzymes, such as NAD+ and TPP. The increased cytosolic ratio of free NADH/NAD+ in cells (more NADH than NAD+) can be caused by diabetic hyperglycemia and by excessive alcohol consumption. Low levels of TPP results from thiamine deficiency.

<span class="mw-page-title-main">PCK2</span> Protein-coding gene in the species Homo sapiens

Phosphoenolpyruvate carboxykinase 2, mitochondrial, is an isozyme of phosphoenolpyruvate carboxykinase that in humans is encoded by the PCK2 gene on chromosome 14. This gene encodes a mitochondrial enzyme that catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP) in the presence of guanosine triphosphate (GTP). A cytosolic form of this protein is encoded by a different gene and is the key enzyme of gluconeogenesis in the liver. Alternatively spliced transcript variants have been described.[provided by RefSeq, Apr 2014]

References

  1. ↑ Nelson DL, Cox MM (2000). Lehninger Principles of Biochemistry. USA: Worth Publishers. p.  724. ISBN   978-1-57259-153-0.
  2. ↑ Silva P. "The Chemical Logic Behind Gluconeogenesis". Archived from the original on August 26, 2009. Retrieved September 8, 2009.
  3. 1 2 Beitz DC (2004). "Carbohydrate metabolism.". In Reese WO (ed.). Dukes' Physiology of Domestic Animals (12th ed.). Cornell Univ. Press. pp. 501–15. ISBN   978-0801442384.
  4. 1 2 Kaleta C, de Figueiredo LF, Werner S, Guthke R, Ristow M, Schuster S (July 2011). "In silico evidence for gluconeogenesis from fatty acids in humans". PLOS Computational Biology. 7 (7): e1002116. Bibcode:2011PLSCB...7E2116K. doi: 10.1371/journal.pcbi.1002116 . PMC   3140964 . PMID   21814506.
  5. ↑ Swe MT, Pongchaidecha A, Chatsudthipong V, Chattipakorn N, Lungkaphin A (June 2019). "Molecular signaling mechanisms of renal gluconeogenesis in nondiabetic and diabetic conditions". Journal of Cellular Physiology. 234 (6): 8134–8151. doi:10.1002/jcp.27598. PMID   30370538. S2CID   53097552.
  6. ↑ Rodwell V (2015). Harper's illustrated Biochemistry, 30th edition. USA: McGraw Hill. p. 193. ISBN   978-0-07-182537-5.
  7. ↑ Ferrier DR, Champe PC, Harvey RA (1 August 2004). "20. Amino Acid Degradation and Synthesis". Biochemistry. Lippincott's Illustrated Reviews. Hagerstwon, MD: Lippincott Williams & Wilkins. ISBN   978-0-7817-2265-0.
  8. 1 2 3 4 Gerich JE, Meyer C, Woerle HJ, Stumvoll M (February 2001). "Renal gluconeogenesis: its importance in human glucose homeostasis". Diabetes Care. 24 (2): 382–91. doi: 10.2337/diacare.24.2.382 . PMID   11213896.
  9. 1 2 3 Garrett RH, Grisham CM (2002). Principles of Biochemistry with a Human Focus. USA: Brooks/Cole, Thomson Learning. pp. 578, 585. ISBN   978-0-03-097369-7.
  10. 1 2 Nuttall FQ, Ngo A, Gannon MC (September 2008). "Regulation of hepatic glucose production and the role of gluconeogenesis in humans: is the rate of gluconeogenesis constant?". Diabetes/Metabolism Research and Reviews. 24 (6): 438–458. doi:10.1002/dmrr.863. PMID   18561209. S2CID   24330397.
  11. ↑ Van Soest PJ (1994). Nutritional Ecology of the Ruminant (2nd ed.). Cornell Univ. Press. ISBN   978-1501732355.
  12. ↑ Rodwell VW, Bender DA, Botham KM, Kennelly PJ, Weil PA (2018). Harper's Illustrated Biochemistry (31st ed.). McGraw-Hill Publishing Company.
  13. ↑ Baynes J, Dominiczak M (2014). Medical Biochemistry (4th ed.). Elsevier.
  14. 1 2 Katz J, Tayek JA (September 1998). "Gluconeogenesis and the Cori cycle in 12-, 20-, and 40-h-fasted humans". The American Journal of Physiology. 275 (3): E537–42. doi:10.1152/ajpendo.1998.275.3.E537. PMID   9725823. Archived from the original on 2017-12-02. Retrieved 2017-07-28.
  15. 1 2 de Figueiredo LF, Schuster S, Kaleta C, Fell DA (January 2009). "Can sugars be produced from fatty acids? A test case for pathway analysis tools". Bioinformatics. 25 (1): 152–8. doi: 10.1093/bioinformatics/btn621 . PMID   19117076.
  16. ↑ Liu F, Thatcher JD, Barral JM, Epstein HF (June 1995). "Bifunctional glyoxylate cycle protein of Caenorhabditis elegans: a developmentally regulated protein of intestine and muscle". Developmental Biology. 169 (2): 399–414. doi: 10.1006/dbio.1995.1156 . PMID   7781887.
  17. 1 2 Kondrashov FA, Koonin EV, Morgunov IG, Finogenova TV, Kondrashova MN (October 2006). "Evolution of glyoxylate cycle enzymes in Metazoa: evidence of multiple horizontal transfer events and pseudogene formation". Biology Direct. 1: 31. doi: 10.1186/1745-6150-1-31 . PMC   1630690 . PMID   17059607.
  18. ↑ Weinman EO, Strisower EH, Chaikoff IL (April 1957). "Conversion of fatty acids to carbohydrate; application of isotopes to this problem and role of the Krebs cycle as a synthetic pathway". Physiological Reviews. 37 (2): 252–72. doi:10.1152/physrev.1957.37.2.252. PMID   13441426.
  19. ↑ Reichard GA, Haff AC, Skutches CL, Paul P, Holroyde CP, Owen OE (April 1979). "Plasma acetone metabolism in the fasting human". The Journal of Clinical Investigation. 63 (4): 619–26. doi:10.1172/JCI109344. PMC   371996 . PMID   438326.
  20. 1 2 Widmaier E (2006). Vander's Human Physiology . McGraw Hill. p.  96. ISBN   978-0-07-282741-5.
  21. 1 2 Mithieux G, Rajas F, Gautier-Stein A (October 2004). "A novel role for glucose 6-phosphatase in the small intestine in the control of glucose homeostasis". The Journal of Biological Chemistry. 279 (43): 44231–44234. doi: 10.1074/jbc.R400011200 . PMID   15302872.
  22. ↑ Chen J, Lee HJ, Wu X, Huo L, Kim SJ, Xu L, et al. (February 2015). "Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain". Cancer Research. 75 (3): 554–565. doi:10.1158/0008-5472.CAN-14-2268. PMC   4315743 . PMID   25511375.
  23. ↑ Yip J, Geng X, Shen J, Ding Y (2017). "Cerebral Gluconeogenesis and Diseases". Frontiers in Pharmacology. 7: 521. doi: 10.3389/fphar.2016.00521 . PMC   5209353 . PMID   28101056.
  24. ↑ Gerich JE (February 2010). "Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications". Diabetic Medicine. 27 (2): 136–142. doi:10.1111/j.1464-5491.2009.02894.x. PMC   4232006 . PMID   20546255.
  25. ↑ Overton TR, Drackley JK, Ottemann-Abbamonte CJ, Beaulieu AD, Emmert LS, Clark JH (July 1999). "Substrate utilization for hepatic gluconeogenesis is altered by increased glucose demand in ruminants". Journal of Animal Science. 77 (7): 1940–51. doi:10.2527/1999.7771940x. PMID   10438042.
  26. 1 2 Donkin SS, Armentano LE (February 1995). "Insulin and glucagon regulation of gluconeogenesis in preruminating and ruminating bovine". Journal of Animal Science. 73 (2): 546–51. doi:10.2527/1995.732546x. PMID   7601789.
  27. 1 2 3 4 Voet D, Voet J, Pratt C (2008). Fundamentals of Biochemistry . John Wiley & Sons Inc. p.  556. ISBN   978-0-470-12930-2.
  28. ↑ Christos Chinopoulos (2020), From Glucose to Lactate and Transiting Intermediates Through Mitochondria, Bypassing Pyruvate Kinase: Considerations for Cells Exhibiting Dimeric PKM2 or Otherwise Inhibited Kinase Activity, https://www.frontiersin.org/articles/10.3389/fphys.2020.543564/full
  29. ↑ Chakravarty K, Cassuto H, Reshef L, Hanson RW (2005). "Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C". Critical Reviews in Biochemistry and Molecular Biology. 40 (3): 129–54. doi:10.1080/10409230590935479. PMID   15917397. S2CID   633399.
  30. ↑ He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA, et al. (May 2009). "Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein". Cell. 137 (4): 635–46. doi:10.1016/j.cell.2009.03.016. PMC   2775562 . PMID   19450513.
  31. ↑ Hatting M, Tavares CD, Sharabi K, Rines AK, Puigserver P (January 2018). "Insulin regulation of gluconeogenesis". Annals of the New York Academy of Sciences. 1411 (1): 21–35. Bibcode:2018NYASA1411...21H. doi:10.1111/nyas.13435. PMC   5927596 . PMID   28868790.
  32. ↑ Wang Y, Tang H, Ji X, Zhang Y, Xu W, Yang X, et al. (January 2018). "Expression profile analysis of long non-coding RNAs involved in the metformin-inhibited gluconeogenesis of primary mouse hepatocytes". International Journal of Molecular Medicine. 41 (1): 302–310. doi:10.3892/ijmm.2017.3243. PMC   5746302 . PMID   29115403.
  33. ↑ Mutel E, Gautier-Stein A, Abdul-Wahed A, Amigó-Correig M, Zitoun C, Stefanutti A, et al. (December 2011). "Control of blood glucose in the absence of hepatic glucose production during prolonged fasting in mice: induction of renal and intestinal gluconeogenesis by glucagon". Diabetes. 60 (12): 3121–31. doi:10.2337/db11-0571. PMC   3219939 . PMID   22013018.
  34. 1 2 Lee S, Dong HH (May 2017). "FoxO integration of insulin signaling with glucose and lipid metabolism". The Journal of Endocrinology. 233 (2): R67 –R79. doi:10.1530/JOE-17-0002. PMC   5480241 . PMID   28213398.
  35. ↑ Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al. (December 2000). "Mechanism by which metformin reduces glucose production in type 2 diabetes". Diabetes. 49 (12): 2063–2069. doi:10.2337/diabetes.49.12.2063. PMC   2995498 . PMID   11118008.Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al. (December 2000). "Mechanism by which metformin reduces glucose production in type 2 diabetes". Diabetes. 49 (12): 2063–2069. doi:10.2337/diabetes.49.12.2063. PMC   2995498 . PMID   11118008. (82  KiB)
  36. ↑ Harrison SA, Lane N (December 2018). "Life as a guide to prebiotic nucleotide synthesis". Nature Communications. 9 (1): 5176. Bibcode:2018NatCo...9.5176H. doi:10.1038/s41467-018-07220-y. PMC   6289992 . PMID   30538225.
  37. ↑ Say RF, Fuchs G (April 2010). "Fructose 1,6-bisphosphate aldolase/phosphatase may be an ancestral gluconeogenic enzyme". Nature. 464 (7291): 1077–1081. Bibcode:2010Natur.464.1077S. doi:10.1038/nature08884. PMID   20348906. S2CID   4343445.
  38. ↑ Muchowska KB, Varma SJ, Moran J (August 2020). "Nonenzymatic Metabolic Reactions and Life's Origins" (PDF). Chemical Reviews. 120 (15): 7708–7744. doi:10.1021/acs.chemrev.0c00191. PMID   32687326. S2CID   220671580.
  39. ↑ Messner CB, Driscoll PC, Piedrafita G, De Volder MF, Ralser M (July 2017). "Nonenzymatic gluconeogenesis-like formation of fructose 1,6-bisphosphate in ice". Proceedings of the National Academy of Sciences of the United States of America. 114 (28): 7403–7407. Bibcode:2017PNAS..114.7403M. doi: 10.1073/pnas.1702274114 . PMC   5514728 . PMID   28652321.
  40. ↑ Ralser M (2018-08-30). "An appeal to magic? The discovery of a non-enzymatic metabolism and its role in the origins of life". The Biochemical Journal. 475 (16): 2577–2592. doi:10.1042/BCJ20160866. ISSN   1470-8728. PMC   6117946 . PMID   30166494.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.